On Feb. 28, 2023, the U.S. Food & Drug Administration (FDA) approved sarilumab (Kevzara) for the treatment of adults with polymyalgia rheumatica (PMR) for whom glucocorticoids have proved inadequate or who cannot tolerate a glucocorticoid taper.1,2 Sarilumab is an interleukin (IL) 6 receptor antagonist. In May 2017, the FDA initially approved the agent for the…
Search results for: adherence
How to Treat Refractory Polymyalgia Rheumatica
Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…
Gout & Its Comorbidities
At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.
The Emotional Toll of Rheumatic Disease
Expressing empathy, engaging patients in conversations about their emotional health and having an overall understanding of grief can help rheumatology health professionals better care for their patients. During a session at ACR Convergence 2023, mental health professionals and patients highlighted how grief affects patients with rheumatic disease and how providers can respond.
2024 Remote Physiologic Monitoring and Therapeutic Monitoring Coding Guidance
This guidance from the ACR provides information about new remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) treatment management codes
Getting to Know the New Foundation President
Liana Fraenkel, MD, MPH, credits much of her own career success to support from the Foundation, and she is eager to advance its mission during her presidency.
Growing Up
SAN DIEGO—In the pre-ACR Convergence 2023 Review Course, Rebecca Sadun, MD, PhD, assistant professor in medicine and pediatrics, Duke University School of Medicine, Durham, N.C., focused on transitions from pediatric to adult rheumatology care for patients with juvenile idiopathic arthritis (JIA).
ARP Welcomes a New President: A Conversation with Aileen Ledingham, PT, MS, PhD
With roots in physical therapy & rehabilitation research, Dr. Ledingham brings to the ARP a deep enthusiasm for volunteering & collaboration, as well as a commitment to building public knowledge about the field of rheumatology.
Are We Making Progress in Treating Lupus? Clinical Insights from Dr. Michelle Petri
At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.
Why Mental Health Screening Is Essential for Patients with Psoriatic Disease
Research suggests that patients with psoriasis and psoriatic arthritis (PsA) have a greater risk of depression, anxiety and, in some cases, substance abuse and dependence than the general population, yet symptoms often go unrecognized and untreated by medical professionals. Both psoriasis and PsA are associated with depression, with up to 30% of patients in either…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 30
- Next Page »